Mercer Global Advisors Inc Editas Medicine, Inc. Transaction History

Mercer Global Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $23,154 - $31,151	3,346 Added 16.54%	23,576 $184,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $29,198 - $52,658	4,591 Added 29.36%	20,230 $166,000
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $109,942 - $180,317	15,639 New	15,639 $113,000
Q1 2021 May 11, 2021	SELL	$39.71 - $90.58 $144,703 - $330,073	-3,644 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $98,643 - $307,371	3,644 New	3,644 $255,000
Q1 2020 May 18, 2020	SELL	$14.88 - $32.78 $100,945 - $222,379	-6,784 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$19.49 - $32.63 $132,220 - $221,361	6,784 New	6,784 $201,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.